Lucila Kerbauy: Precision Medicine in AML and CAR Cells
Lucila Kerbauy, Head of Cell Therapy Center at Einstein Hospital Israelita, reposted from Larissa Zanetti, on LinkedIn:
“I’m very happy and proud to share another publication from our group on CAR-T cell therapy for acute myeloid leukemia (AML).
A special thank you to our team and collaborators who make this work possible. Advancing innovative and accessible cell therapies in Brazil and beyond is truly a collective effort.”
Quoting Larissa Zanetti’s post:
“It’s out!
I’m very proud to share our recent publication, “Precision Medicine in AML and CAR Cells: Where Are We?” — a collaborative effort uniting two leading research groups from our institution.
In this work, we explore how precision medicine and CAR-based cellular therapies (CAR-T and CAR-NK) are converging to transform the landscape of acute myeloid leukemia (AML) treatment. The review highlights the critical role of patient-specific approaches, novel target discovery, and next-generation cell engineering in shaping the future of personalized immunotherapy.
I truly believe that as the field of advanced cell therapies continues to expand, the integration of precision medicine principles will become increasingly essential.
A huge thank you to my incredible collaborators and mentors who made this work possible.”
Article: Precision medicine with car cells in acute myeloid leukemia: where are we?
Authors: Larissa C. Zanetti, Victoria Tomaz, Ingrid Ferreira de Souza, Paulo V. Campregher, Nelson Hamerschlak, Lucila N. Kerbauy
Read the full article here.
Stay updated on all scientific advances with Hemostasis Today.
-
Mar 13, 2026, 17:06Srishti Goyal: Can Thalassemia Major Be Prevented?
-
Mar 13, 2026, 16:59Tagreed Alkaltham: Preventing the Risk of Transfusion Reactions Before They Occur
-
Mar 13, 2026, 16:52Giuseppe Lippi: New Insights Into Antiphospholipid Antibodies and Cardiovascular Thrombosis
-
Mar 13, 2026, 16:51Ahmet Dirican: Apixaban vs Rivaroxaban in Acute VTE
-
Mar 13, 2026, 16:47Sinju Thomas: Combined Red Cell and Plasma Exchange for Severe FES in Sickle Cell Disease
-
Mar 13, 2026, 16:44Michael Makris: Lower Bleeding Risk With Apixaban vs Rivaroxaban in Acute Venous Thrombosis
-
Mar 13, 2026, 16:36Muhammad Bilal: Principles and Clinical Uses of the Coombs Test
-
Mar 13, 2026, 16:27Nikhil Ganjoo: Early Detection of Rare Diseases Through Newborn Genome Sequencing
-
Mar 13, 2026, 16:18Tareq Abadl: Anemia of Inflammation – Hepcidin Regulation of Iron